特宝生物：派格宾增加适应症拟纳入优先审评程序
下载客户端
独家抢先看
独家抢先看
【特宝生物：派格宾增加适应症拟纳入优先审评程序】财联社5月7日电，特宝生物公告，派格宾增加适应症拟纳入优先审评程序。派格宾联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎。
“特别声明：以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布，本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”
